Rosetta Genomics to Present at Scientific Conference; Provides Update on Colon Cancer Diagnostic Program

REHOVOT, Israel & PHILADELPHIA--(BUSINESS WIRE)--Rosetta Genomics (NASDAQ: ROSG) today announced that Ayelet Chajut, its Executive Vice President, R&D, Head of Molecular Biology will speak at the 6th International Conference on Circulating Nucleic Acids in Plasma and Serum (CNAPS-VI). The conference will be held November 9 through 11 in Hong Kong. Dr. Chajut’s presentation, “Circulating microRNA as a new generation of molecular diagnostic markers” will be made November 11.

Dr. Chajut will discuss the Company’s development of microRNA-based technologies with a particular emphasis on the extraction of microRNAs from body fluids, especially serum and the progress in using microRNAs as biomarkers for the early detection of cancer will be discussed. Dr. Chajut will provide an update on the Company’s efforts to develop a serum-based colon cancer screening. This update includes a discussion of the program and results to date.

“Although we have a commercial product using tissue biopsy called miRview™ mets that can identify as many as 25 cancer types, our work with the colon cancer project is meant to identify colon cancer alone. The identified microRNA potential biomarkers were recognized on serum samples obtained from colon cancer patients only, in comparison to samples derived from control individuals. Our first set of 128 samples yielded preliminary results with 91% sensitivity and 72% specificity, while our second set of 138 samples, resulted in 85% sensitivity and 70% specificity using a different pair of microRNA biomarkers. We continue to gather additional samples for validation, and also are reviewing the behavior of microRNAs in healthy individuals compared with colon cancer patients,” Dr. Chajut said.

Rosetta points out that the colon cancer serum project is still in the early stage of development, and the company can provide no assurance that it will be successful in developing this product in its intended timeframe, or at all. In addition, Rosetta can provide no assurance that any final product will effectively differentiate colon cancer patients from patients with other cancers. All statements related to its intention and ability to successfully develop a minimally-invasive colon cancer screening diagnostic test are forward-looking statements. These statements are based on management’s current expectations and actual events or results may differ materially and adversely from these expectations for a variety of reasons. Also, until the final assay is finalized and validated by Rosetta’s CLIA-certified lab in Philadelphia there is no guarantee that the statistical performance of Rosetta’s test during the development process will be the same or similar to that of any final product.

The Company will also present proof-of-concept results on its discovery that physiological changes occur in the MicroRNA of pregnant women and these pregnancy-related microRNAs can be measured in serum.

About Rosetta Genomics

Rosetta Genomics is a leading molecular diagnostics company developing and commercializing molecular diagnostic products based on its proprietary microRNAs. Rosetta Genomics is working to develop early detection cancer screening products, including a colon cancer screening test. Rosetta performs its commercial molecular diagnostics tests at Rosetta Genomics Laboratories in Philadelphia.

Forward-Looking Statements

Various statements in this release concerning Rosetta’s future expectations, plans and prospects, including without limitation, statements relating to the development of early detection cancer screening products, including a minimally-invasive colon cancer screening test, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed under “Key Information - Risk Factors” in Rosetta’s Annual Report on Form 20-F for the year ended December 31, 2007 on file with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Company Contact:
Rosetta Genomics
Ron Kamienchick, 215-382-9000 ext 318
investors@rosettagenomics.com
or
Investor Contacts:
Lippert/Heilshorn & Associates
Kim Sutton Golodetz, 212-738-3777
kgolodetz@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com